Articles On Oncosil Medical (ASX:OSL)

There’s been a breakthrough in acne treatment Scientists have found a way to use skin bacteria to control sebum production We look at the best and worst performing ASX health stocks in the past month   Scientists have made a significant b...

The ASX pared gains after the CPI came in stronger than expected Fortescue led the Mining sector after its quarterly update TikTok’s ban in the US looms   The ASX closed modestly higher today by +0.1% as gains were pared after the release...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

The ASX extends its gains on Tuesday Tech stocks rallied ahead of US megacap earnings, while goldies struggled Tesla, along with Alphabet and Spotify, will release results tonight   The ASX200 lifted on Tuesday, up by +0.45% after trackin...

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

Pancreatic cancer treatment device company OncoSil Medical (ASX:OSL) has announced the first treatment utilising the OncoSil device on a patient residing in Turkey.

Stockhead’s Top 10 at 10, published at ~10.40am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...

OncoSil Medical (ASX:OSL), in its ongoing mission to develop treatments for pancreatic cancer, says the first patient treatment using the OncoSilTM device for its TRIPP-FXX clinical study has been conducted at the prestigious Hammersmith Ho...

The ASX200 closed up slightly by +0.1% on Monday as gains in tech and gold stocks were offset by losses in the energy sector.  Energy stocks struggled as crude prices fell more than US$1 a barrel in Asian hours today after Israel confirmed...

The ASX200 has closed down .56 of a per cent with IT down 1.4 per cent and in the red for a second straight day, materials slumping 0.8 per cent and real estate shedding .61 per cent. Coming into sharp focus today were OncoSil Medical, T...

The ASX200 is down nearly .7 of a per cent – almost on par with futures’ predictions – with most sectors, apart from energy, in the red. The Australian Bureau of Statistics released data showing that imported goods rose by 4.8 per cent i...

OncoSil Medical (ASX:OSL) – on its mission to combat pancreatic cancer – has now dosed the first two patients in Austria with the use of the OncoSilTM device. In early trade Oncosil shares catapulted as much as 30 per cent after announci...

The ASX200 ends Tuesday slightly lower Resources stocks hold the fort, everyone else AWOL  Small Caps led by Dart Mining and Mesoblast   Local stocks looked the goods during the first hour of the new quarter, but that – like the ASX200’s...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

The ASX200 has ended Friday down 0.15pc, but ends week higher Property and Healthcare gains offset by Resources losses  Small Caps led by Gold50   Wall Street hit more record highs on Thursday in New York, the Australian market on Friday,...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end hopelessly, slightly lower IT sector surges 2.9%   Small Caps led by incredible Nyrada outperformance   Despite a return to form for lithium and a stunning 420% rally for little local drugmaker Nyrada, the ASX200 was t...

  Local markets are lucky to close a smidgen higher IT and Healthcare sectors offset a 2pc loss for Energy Small Caps led by Enova Mining   Australian sharemarkets lacked all the vim, vigour and vinegar one associates with victory on Mond...

  Local markets end slightly lower Telco Sector jumps 1.5pc Small Caps led by Way2Vat   The ASX200 has ended a second slumbrous session slightly lower, with a little dribble in the shape of the Star Casino at the corner of its mouth. US M...

ASX adds 0.7pc to close out the week in a positive frame of mind IT and materials rise, thanks to a softening US dollar and general commodity weirdness Small caps led by NKOTB, Australian Wealth Advisors Group on a solid debut   Materi...

ASX rises 0.77pc, hefted heavenward with the help of a huge tech buy InfoTech was the best of the sectors, up 6.81pc by day’s end Small cap winners included James Bay Minerals, Bellavista Resources and Way2VAT   Local markets have stru...

Good morning, and welcome to Stockhead’s Top 10 at shortly-before-11-ish, which is meant to highlight the best (and sometimes worst) performing ASX stocks in morning trade using live data, to provide a short, sharp update to help frame the...

ASX to gain on Wednesday after dovish comments from US Fed Gold price continues to climb, nears all time high Deutsche Bank is positive about equities’ prospects in 2024   Aussie shares are poised to edge higher again on Wednesday after m...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

The ASX has ended -0.4% lower, just 2.5 points from 2023 parity Utilities only sector in green Small caps led by 4DX, Infinity and a few Lake Johnston lithium plays   The local market is back to digging its little hole from which it may t...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

L’Oréal to take minority stake in Chinese startup Shinehigh Innovation Shinehigh is developing supramolecular technology which could be used in the fashion industry Best and worst performing ASX biotechs over the past couple of weeks   Be...

The FDA has just approved an emergency use authorisation for new Covid-19 vaccines What is emergency use authorisation, and which ASX stocks have got it? We look at the best and worst performing ASX biotechs over the couple of weeks   On...

Earnings reports dominated headlines in August Despite solid results from ASX healthcare giants, the sector finished lower We take a look at which ASX healthcare stocks performed the best in August   August was all about earnings, and des...

Australian biotech has attracted US investments in the last five years Among ASX stocks to get funded from the US include Opthea We look at the  best and worst performing ASX biotechs over the past month   The Australian biotech sector co...

ASX 200 benchmark rises almost 0.6% Tech Sector recovers Wednesday’s losses, after Nasdaq positivity  Miners lead small cap gains, ERW, RDN, AZS winning at home in Andover South   The Australian share market was up and about early on Thur...

Biotech could be a US$4 trillion industry in 10 years Genetic engineering and weight loss are two growing themes in the space We look at the best and worst performing ASX biotechs over the past month   Steve Jobs used to say that the most...

The end of pandemic and higher rates have subdued biotech market But there are signs now the sector is making a comeback We take a look at the ASX Biotech Winners in July   The Covid-19 pandemic had produced windfalls for and attracted fa...

OncoSil Medical (OSL) gains ethics committee approval for its PANCOSIL trial, focused on treating patients with locally advanced pancreatic cancer (LAPC) The company will recruit 15 patients for treatment using its OncoSil device via a p...

OncoSil gets Ethics committee approval Starpharma’s  nasal spray VIRALEZE granted approval in Malaysia Botanix Pharmaceuticals strikes deal in Korea   Medical device OncoSil Medical (ASX:OSL) rose 8% this morning after the Ethics committe...

Biotech is making a comeback in 2023 There’s been a couple of breakthroughs on the ASX this year We take a look at the ASX biotech winners in May   There are clear signs the biotech sector is springing back to life after a disappointing 2...

The ASX fell this morning and – sadly – just never recovered. It’s down 0.64%. Aside from Happy Times among the lithium players, it’s been a total snoozefest Rubix Resources (ASX:RB6) takes bragging rights with a 41.6% hike for the day  ...

OncoSil Medical (ASX:OSL) has announced the first patient treatment in Italy with its OncoSil device.

OncoSil Medical (OSL) treats its first patient in Italy with the Oncosil device, its flagship product for pancreatic cancer treatment The first patient treatment was carried out at the San Camilo-Forlanini Hospital in Rome, a significant...

The ASX opened lower this morning, while majority of the sectors dragged. Finance and communications fell 0.5 per cent, while healthcare also took a hit – down 0.13 per cent. However, Amplia Therapeutics (ATX) appeared immune to the...

S&P/ASX 200 closes up 0.40%, while the emerging companies index rises 0.43% Algerian mining regulator issues a mining permit for Terramin’s Tala Hamza zinc-lead project Retail component of Next DC’s entitlement offer opens and is expec...

OncoSil Medical (OSL) enrols the first patient into its randomised clinical study of its namesake OncoSil device to be used in combination with Folfirinox chemotherapy OSL plans to recruit 80 patients across 15 hospital sites in the UK a...

Artificial intelligence is set to disrupt the healthcare sector AI could also help in drugs discovery Telix delivers first quarterly revenue of $100 million   Moody’s Analytics’ chief economist, Mark Zandi, said the healthcare industry’s...

Medical device company OncoSil (ASX:OSL) has announced the findings of an oral presentation at The Mayo Clinic IMPACT Course 2023 by Dr Frank Weilert from Waikato Hospital in New Zealand.

ASX closes 5 points lower, down 0.08% after a day of ups and downs Goldies are the clear winners again, up 1.96% and well ahead of the market Mt Monger does well with a 23% gain to be over +130% for the month   After an early grimace-indu...

ASX 200 benchmark closes 0.11% lower after a fickle day on the bourse Iron ore price drops to five month lows, making (almost) everyone sad Larvotto ends up on top of the Small Caps, adding 61.9% for the day   Aussie markets were a tad me...

OncoSil Medical (OSL) makes further commercial progress in Spain with its namesake OncoSil brachytherapy device for the treatment of pancreatic cancer The company says the first patient treated with OncoSil in Spain has undergone success...

Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest movers...